Search jobs Meningococcal Vaccine Market to Receive Impetus from Introduction of a Series of Broad-range, Low-cost Vaccines Meningococcal meningitis is a rare but potentially devastating bacterial infection that targets the brain. Despite growing advances in medical care, the disease can kill the host within a relatively lesser timespan. One in 10 meningococcal meningitis patients die from the disease, and ~15% of the survivors suffer from deadly complications, which typically include brain damage, deafness, or/and amputation. Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focusing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not for profits like the Global Alliance for Vaccines and Immunization (GAVI).